“The data to be presented at the upcoming
ECCMID 2022 conference suggests the significant potential of BTX 1801 to prevent S. aureus
bloodstream infections associated with considerable morbidity, mortality, and cost in haemodialysis
patients who use Central Venous Catheters (CVC).”
“We look forward to sharing the compelling BTX 1801 data with leading infectious disease experts at
the upcoming EDDMID 2022 conference.”
Ann: Upcoming BTX 1801 Data Presentations at European Congress, page-7
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.020(5.48%) |
Mkt cap ! $543.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.5¢ | 33.5¢ | $4.668M | 13.46M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 542398 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |